Drug helps brain tumor patients live longer

Jan 28, 2008

People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the January 29, 2008, issue of Neurology.

“Our findings show high-dose methotrexate alone or in combination with other chemotherapy drugs is the most effective treatment available for primary central nervous system lymphoma (PCNSL)” said study author Tracy Batchelor, MD, with the Massachusetts General Hospital Cancer Center in Boston. PCNSL can be a potentially curable brain tumor or one in which there can be a long remission.

The research involved 25 adults with newly diagnosed PCNSL who received a high dose of methotrexate every two weeks for four months or until there were no signs of the brain tumor. The participants were then followed for a minimum of 6.5 years.

The article found 52 percent of the participants achieved complete remission and 40 percent of these patients have not relapsed after an average of seven years. The average survival rate of all participants who received methotrexate was 4.5 years. In contrast, the average survival rate for patients who receive radiation therapy for this type of brain tumor is one year.

“Our findings support the role of methotrexate as a critical chemotherapy drug in the treatment of this type of brain tumor,” said Batchelor. “Moreover, it appears some people may achieve a long remission through the methotrexate alone.”

Batchelor says further studies are needed to identify the optimal methotrexate dose and combination therapy that will produce the most effective results with minimum side effects.

Source: American Academy of Neurology

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

Microsoft beefs up security protection in Windows 10

2 hours ago

What Microsoft users in business care deeply about—-a system architecture that supports efforts to get their work done efficiently; a work-centric menu to quickly access projects rather than weather readings ...

US official: Auto safety agency under review

15 hours ago

Transportation officials are reviewing the "safety culture" of the U.S. agency that oversees auto recalls, a senior Obama administration official said Friday. The National Highway Traffic Safety Administration has been criticized ...

Out-of-patience investors sell off Amazon

15 hours ago

Amazon has long acted like an ideal customer on its own website: a freewheeling big spender with no worries about balancing a checkbook. Investors confident in founder and CEO Jeff Bezos' invest-and-expand ...

Ebola.com domain sold for big payout

15 hours ago

The owners of the website Ebola.com have scored a big payday with the outbreak of the epidemic, selling the domain for more than $200,000 in cash and stock.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0